Abstract
In the case of major psychiatric disorders such as schizophrenia, shortcomings in the conversion of scientific discoveries into newer and safer treatment options has led to a loss of confidence and precipitated a crisis for large pharmaceutical companies. This chapter describes how incorporation of multiplex biomarker approaches into the clinical pipeline can lead to better patient characterization, delivery of novel treatment approaches and help to renew efforts in this important area. The development of specific biomarker test panels for disease prediction should facilitate early intervention strategies, which may help to slow disease development or progression. Furthermore, the development of such tests using lab-on-a-chip and smartphone platforms will help to shift diagnosis and treatment of this major disorder into a point-of-care setting for improved patient outcomes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Publishing, Arlington, VA. ISBN 10: 0890425558
World Health Organization (1 Jan. 1992) ICD-10: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organisation. ISBN-10: 9241544228
Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205:88–94
Jablensky A (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 250:274–285
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586
Liu Y, Dalal K, Stollenwerk B (2013) The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles. PLoS One 8:e61718
Tsuang MT (1975) Heterogeneity of schizophrenia. Biol Psychiatry 10:465–474
Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J et al. (1998) First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 50:41–44
Follette WC, Houts AC (1996) Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J Consult Clin Psychol 64:1120–1132
Yolken RH, Dickerson FB, Fuller TE (2009) Toxoplasma and schizophrenia. Parasite Immunol 31:706–715
Lovatt A, Mason O, Brett C, Peters E (2010) Psychotic-like experiences, appraisals, and trauma. J Nerv Ment Dis 198:813–819
Clayton PJ, Guze SB, Cloninger CR, Martin RL (1992) Unipolar depression: diagnostic inconsistency and its implications. J Affect Disord 26:111–116
Bromet EJ, Kotov R, Fochtmann LJ, Carlson GA, Tanenberg-Karant M, Ruggero C et al. (2011) Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 168:1186–1194
Torrey EF (1992) Are we overestimating the genetic contribution to schizophrenia? Schizophr Bull 18:159–170
McGue M (1992) When assessing twin concordance, use the probandwise not the pairwise rate. Schizophr Bull 18:171–176
Tsuang M (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210–220
Dauncey MJ, Bicknell RJ (1999) Nutrition and neurodevelopment: mechanisms of developmental dysfunction and disease in later life. Nutr Res Rev 12:231–253
Schlotz W, Phillips DI (2009) Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun 23:905–916
Koenig JI, Kirkpatrick B, Lee P (2002) Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 27:309–318
Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–489
Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481–445
Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al. (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15:118–119
Szulc A, Galińska B, Konarzewska B, Gudel-Trochimowicz I, Popławska R (2001) Immunological marker activity in first episode schizophrenic patients. Pol Merkur Lekarski 10:450–452
Van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG et al. (2012) Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull 38:272–279
Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD et al. (2014) Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull 41:419–428
Chan MK, Krebs MO, Cox D, Guest PC, Yolken RH, Rahmoune H et al. (2015) Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry 5, e601. doi:10.1038/tp.2015.91
Agius M, Shah S, Ramkisson R, Murphy S, Zaman R (2007) Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team. Preliminary results. Psychiatr Danub 19:10–19
Salokangas RK, McGlashan TH (2008) Early detection and intervention of psychosis. A review. Nord J Psychiatry 62:92–105
Yap HL (2010) Early psychosis intervention. Singapore Med J 51:689–693
Thomas P (2004) The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord 79(Suppl 1):S3–S8
Hirschfeld RM (2001) Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry 62(Suppl 14):5–9
Post RM (2005) The impact of bipolar depression. J Clin Psychiatry 66(Suppl 5):5–10
Kamel N, Compton C, Middelveld R, Higenbottam T, Dahlén SE (2008) The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur Respir J 31:924–926
Hunter AJ (2008) The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today 13:371–373
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.ht
Ellington AA, Kullo IJ, Bailey KR, Klee GG (2010) Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 56:186–193
Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H et al. (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069–1071
Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14:1–10
Meyer U, Feldon J, Yee BK (2009) A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35:959–972
Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E (2007) Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46
Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R et al. (2011) Regulation of immunemodulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry 12:201–215
Montejo AL (2010) The need for routine physical health care in schizophrenia. Eur Psychiatry 25(Suppl 2):S3–S5
Pedrini M, Massuda R, Fries GR, de BittencourtPasquali MA, Schnorr CE, Moreira JC, et al. (2012) Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46:819–824
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671
Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC et al. (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 5:39–47
Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. (2012) Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17: 494–502
Späth-Schwalbe E, Born J, Schrezenmeier H, Bornstein SR, Stromeyer P, Drechsler S et al. (1994) Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 79:1212–1214
Straub RH, Buttgereit F, Cutolo M (2011) Alterations of the hypothalamic-pituitaryadrenal axis in systemic immune diseases – a role for misguided energy regulation. Clin Exp Rheumatol 29:S23–S31
Bremner JD (2006) Traumatic stress: effects on the brain. Dialogues Clin Neurosci 8:445–461
Spijker AT, van Rossum EF (2012) Glucocorticoid sensitivity in mood disorders. Neuroendocrinology 95:179–186
Müller N, Riedel M, Schwarz MJ (2004) Psychotropic effects of COX-2 inhibitors – a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37:266–269
Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a doubleblind, randomized and placebo-controlled trial. Schizophr Res 90:179–185
Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M et al. (2010) Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebocontrolled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121:118–124
Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520–527
Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first episode schizophrenia patients. J Clin Psychiatry 65:1335–1342
Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 51:382–386
van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L et al (2008) Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93:572–577
Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011(36):1092–1096
Taguchi A, Wartschow LM, White MF (2007) Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317:369–372
Convit A (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26(Suppl 1):31–35
Craft S (2007) Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147–152
Bello NT, Hajnal A (2006) Alterations in blood glucose levels under hyperinsulinemia affect accumbens dopamine. Physiol Behav 2006(88):138–145
O’Malley D, Shanley LJ, Harvey J (2003) Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology 44:855–863
Corcoran CM, Smith C, McLaughlin D, Auther A, Malaspina D, Cornblatt B (2012) HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res 135:170–174
Gorobets LN, Matrosova MI (2010) Specialties of prolactin secretion and peripheral reproductive sex hormones in patients with of first episode of schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 110:17–22
Akiibinu MO, Ogundahunsi OA, Ogunyemi EO (2012) Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 5:169
Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110–116
Tannenbaum GS, Martin JB, Colle E (1976) Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. Endocrinology 99:720–727
Meltzer HY, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59:19–27
Bahtiyar G, Weiss K, Sacerdote AS (2007) Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract 13:601–608
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPARgamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626–1633
Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R et al (2005) Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 79:251–256
Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al (2011) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 72:1552–1557
Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615–1616
Zhang JP, Malhotra AK (2011) Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7:9–37
Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC et al (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43:620–626. doi:10.1016/j.jpsychires.2008.11.001, Epub 2008 Dec 24
Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R et al (2016) Predicting weight gain in patients treated with clozapine: the role of sex, body mass index, and smoking. J Clin Psychopharmacol 36:120–124
Shrivastava A, Johnston M, Bureau Y, Shah N (2012) Baseline serum prolactin in drug naive, first-episode schizophrenia and outcome at five years: is it a predictive factor? Innov Clin Neurosci 2012(9):17–21
Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S (2012) Identification of blood based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry 2, e82
Schwarz E, Steiner J, Guest PC, Bogerts B, Bahn S (2015) Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World J Biol Psychiatry 16:22–30
Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJ et al (2016) Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun 52:178–186
Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5(2):e9166
Salmon SE, Mackey G, Fudenberg HH (1969) “Sandwich” solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol 103:129–137
Salmon SE, Smith BA (1970) Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. J Immunol 104:665–672
Schumacher S, Nestler J, Otto T, Wegener M, Ehrentreich-Förster E, Michel D et al (2012) Highly-integrated lab-on-chip system for point-of-care multiparameter analysis. Lab Chip 12:464–473
Krishna S, Boren SA, Balas EA (2009) Healthcare via cell phones: a systematic review. Telemed J E Health 15:231–240
Berg B, Cortazar B, Tseng D, Ozkan H, Feng S, Wei Q et al (2015) Cellphone-based hand-held micro-plate reader for point-of-care testing of enzyme-linked immunosorbent assays. ACS Nano 9:7857–7866
Acknowledgments
D.M.S. and the Laboratory of Neuroproteomics, UNICAMP are funded by FAPESP (São Paulo Research Foundation) grant number 13/08711-3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Steiner, J., Guest, P.C., Rahmoune, H., Martins-de-Souza, D. (2017). The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients. In: Guest, P.C. (eds) Multiplex Biomarker Techniques. Methods in Molecular Biology, vol 1546. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-6730-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6730-8_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-6729-2
Online ISBN: 978-1-4939-6730-8
eBook Packages: Springer Protocols